Felix Gerhard Maria Dietlein, M.D., Ph.D.
This page shows the publications Felix Dietlein has written about Xenograft Model Antitumor Assays.
A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov. 2014 May; 4(5):592-605.
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget. 2015 Nov 17; 6(36):38458-68.
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.